Ruiz Carreño, Paula

Person:
Ruiz Carreño, Paula

Name

Ruiz Carreño, Paula

publication.page.department

Universidad de Murcia. Departamento de Atención Sociosanitaria

Full item page

Search Results

Now showing 1 - 6 of 6

Open Access
Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer
(Springer, 2026-01-20) Alonso Romero, José Luis; Martínez-García, Jerónimo ; Carrillo-Vicente, Raúl ; Fernández Aramburo, Antonio ; Ferrando Díez, Angélica ; Sánchez Henarejos, Pilar ; de la Morena Barrio, Pilar ; Puertes Boix, Ana ; Jiménez, Mª Dolores; Peña Siles, Joaquín; Parejo Maestre, José Antonio; de las Heras Rubio, Antonio ; Ruiz Carreño, Paula; Medicina; Facultades de la UMU::Facultad de Medicina
Background Data on neoadjuvant treatment with trastuzumab biosimilars, particularly CT-P6, in combination with pertuzumab, are limited. This study evaluates the efficacy, tolerability, and immunogenicity of CT-P6 plus pertuzumab and chemotherapy, in routine clinical practice for HER2-positive early breast cancer, including translational biomarker analyses related to pathologic complete response (pCR). Methods Prospective, multicenter, observational study in 102 patients with HER2-positive early breast cancer. Patients received hospital-preferred neoadjuvant regimens protocols, with (scheme 1 and 3) or without anthracyclines (scheme 2). The primary endpoint was pCR, defined as the absence of invasive tumor in both the breast and axillary lymph nodes (ypT0/ypTis and ypN0). Translational endpoints included soluble HER2, anti-trastuzumab CT-P6 antibodies, and exploratory response-related modeling approaches supported by machine learning techniques. Results Among patients who underwent surgery, pCR (ypT0/ypTis and ypN0) was achieved in 57.43% of cases, with no significant differences between anthracycline-based and non-anthracycline-based regimens. Soluble HER2 and anti-trastuzumab CT-P6 antibodies were not significantly associated with pCR. Treatment was well-tolerated; the most relevant Grade 3–4 treatment-related adverse events were diarrhea (2.25%) and asthenia (0.50%). No immunogenicity or clinically relevant cardiotoxicity was observed. Conclusions Trastuzumab CT-P6 combined with pertuzumab and chemotherapy can be used in neoadjuvant treatment for HER2-positive early breast cancer, showing pCR rates comparable to the reference trastuzumab and without evidence of immunogenicity. Exploratory analyses of soluble HER2 and anti-trastuzumab CT-P6 antibodies did not demonstrate a significant association with pCR, although this possibility cannot be excluded. Their assessment contributes to the translational understanding of biosimilar integration into curative regimens.
Open Access
Estudio de los problemas de salud en mujeres supervivientes al cáncer de mama.
(Universidad de Murcia. EDITUM, 2014) Almansa Martínez, Pilar; Ruiz Carreño, Paula; Enfermería
Open Access
Drug cost avoidance analysis of cancer clinical trials in Spain: a study on cost contributors and their impact
(BioMed Central, 2022-07-26) Sánchez Martínez, Domingo Antonio; Salas Lucia, Federico; Jiang, Hanzi; Alonso Romero, José Luis; Ruiz Carreño, Paula; Medicina
Objective Analyze the cost contributors and their impact on the drug cost avoidance (DCA) resulting from cancer clinical trials over the period of 2015–2020 in a tertiary-level hospital in Spain (HCUVA). Methods We performed a cross-sectional, observational, retrospective study of a total of 53 clinical trials with 363 patients enrolled. We calculated the DCA from the price of the best standard of care (i.e.: drugs that the institution would otherwise fund). A linear regression model was used to determine cost contributors and estimate their impact. Results The total DCA was ~ 4.9 million euros (31 clinical trials; 177 enrollees), representing ~ 30% and ~ 0,05% approximately of the annual pharmaceutical expenditures at the HCUVA and for the Spanish Health System, respectively. Cancer type analysis showed that lung cancer had the highest average DCA by trial, indicating that treatments in these trials were the most expensive. Linear regression analysis showed that the number of patients in a trial did not significantly affect that trial's DCA. Instead, cancer type, phase trials, and intention of treatment were significant cost contributors to DCA. Compared to digestive cancer trials, breast and lung trials were significantly more expensive, (p < 0.05 and p < 0.1, respectively). Phase III trials were more expensive than Phase II (p < 0.01) and adjuvant trials were less expensive than palliative (p < 0.05). Conclusion We studied cost contributors that significantly impacted the estimated DCA from cancer clinical trials. Our work provides the groundwork to explore DCA contributors with potential to enhance public relations material and serve as a negotiating tool for budgeting, thus playing an important role to inform decisions about resource allocation.
Open Access
Clinical Complete Response and Organ Preservation Strategies in Rectal Cancer: A Real-World Single-Center Experience Clinical Complete Response and Organ Preservation in Rectal Cancer
(MDPI, 2026-02-27) Encarnación, J.A. ; Ibáñez, N. ; de la Fuente, I.; González, S. ; Sánchez, M.; Bautista, Y. ; Rodríguez, C.; Nadal, J.A. ; Abellán, I. ; Montoya, M.; Ono, A. ; Carbonell, G.; Frutos, L. ; Ortiz, E.; Manso, C. ; Ruiz Carreño, Paula; Marín Vera, Miguel; Quiles, B.; Abrisqueta Carrión, Jesús; Royo-Villanova Reparaz, Carlota; Alonso Romero, José Luis; Marín-Zafra, G.; Guirao, M.; Hernández, Q.; Medicina Interna; Facultades de la UMU::Facultad de Medicina
Background: The management of rectal cancer has evolved toward response-adapted strategies, including organ preservation in selected patients achieving a clinical complete response (cCR) after neoadjuvant treatment. However, most available evidence derives from clinical trials, and data from real-world clinical practice remain limited. Methods: We conducted a retrospective observational cohort study including consecutive patients with rectal adenocarcinoma treated at a tertiary referral center between January 2021 and December 2025. Baseline clinical, tumor-related, and treatment characteristics were collected. Tumor response was assessed using clinical, endoscopic, and radiological criteria. The primary endpoint was the rate of clinical complete response and the implementation of watch-and-wait strategies. Secondary endpoints included recurrence patterns and exploratory oncologic outcomes according to baseline tumor characteristics. Results: A total of 229 patients were identified, of whom 148 were evaluable for treatment response. Clinical complete response was documented in 56 patients (37.8%), and a watch-and-wait strategy was implemented in 42 patients (28.4%). Higher cCR rates were observed in patients with stage I–II disease and in tumors measuring < 4 cm on baseline magnetic resonance imaging, with cCR rates exceeding 55% in this subgroup. Tumors ≥ 4 cm showed substantially lower response rates. Clinical complete responses were observed across both short-course radiotherapy plus chemotherapy and long-course chemoradiotherapy regimens in patients with small tumors and early-stage disease. Tumor distance from the anal verge was not consistently associated with response. With a median follow-up of 26 months in the watch-and-wait group, five recurrences were observed, including three local recurrences. Conclusions: In this real-world cohort, baseline tumor size and clinical stage were the main determinants of clinical complete response and eligibility for organ-preservation strategies in rectal cancer. Small tumors (<4 cm) showed high response rates regardless of neoadjuvant regimen. These findings support response-adapted, individualized treatment strategies and highlight the importance of tumor burden in selecting candidates for non-operative management in routine clinical practice.
Open Access
Estudio sobre la calidad de vida en mujeres supervivientes al cáncer de mama
(2015-06-24) Ruiz Carreño, Paula; Almansa Martínez, Pilar; Campos Aranda, Matilde; Facultad de Enfermería
Introducción El cáncer de mama constituye un problema de salud de gran repercusión en la población femenina por su alta incidencia. Debido a que su pronóstico ha mejorado notablemente en los últimos años y la supervivencia actualmente es elevada, el propio proceso y los tratamientos que se aplican tienen importantes repercusiones personales y familiares. En la actualidad, el cáncer de mama no es percibido como una enfermedad terminal, sino como un proceso crónico de larga duración, las estadísticas confirman que se trata de una grave amenaza para la mujer por las secuelas que produce. Objetivos 1) Estudiar la calidad de vida (CV) en mujeres supervivientes entre 5 y 8 años al cáncer de mama, identificando las secuelas físicas y psicológicas que sufren. 2) Determinar el porcentaje de las mujeres supervivientes al cáncer de mama entre 5 y 8 años que padecen cada una de las secuelas. 3) Determinar el porcentaje de las mujeres supervivientes al cáncer de mama entre 5 y 8 años que tienen alterada su CV. 4) Estudiar qué factores sociodemográficos y clínicos están relacionados con la gravedad que presentan las secuelas y por lo tanto influyen en la CV de estas mujeres. Metodología Es un estudio observacional y transversal. Con 120 mujeres supervivientes al cáncer de mama entre 5 y 8 años de diagnóstico. Instrumento de medida: cuestionarios de la EORTC QLQ-C30+ BR23 adaptados. Para el análisis de los datos se realizaron diferentes pruebas estadísticas (estudio descriptivo, distribución de frecuencias absolutas y relativas, análisis factorial, estimaciones de parámetros con un nivel de confianza al 95%, contrastes de una proporción, contrastes del Coeficiente de Correlación de Pearson, el Test de la χ2 de Pearson, la T de Student combinada y el test no exacto de Brown-Forsythe) Resultados La edad media de la muestra es de 51,76 años (D.E. 8,97), el 72,5% están casadas, el 46,7% tienen 2 hijos, 38,3% han sido sometidas a cirugía conservadora, y el 58,3% recibieron quimioterapia+ radioterapia+ terapia hormonal. Tras la realización del análisis factorial se destacan las siguientes dimensiones: problemas del brazo (22,5% de estas mujeres tienen alterada la CV), estado físico (20%), satisfacción de la imagen corporal (22,5%), estado emocional (20,8%), funcionamiento social (7,5%), funcionamiento sexual (60%), problemas de alimentación (2,5%) y molestias en la mama (38,3%). Conclusión Tres de cada cuatro mujeres supervivientes entre 5 y 8 años al cáncer de mama, tienen alterada su CV que se ve afectada por las siguientes secuelas: problemas del brazo, estado físico, problemas de alimentación, problemas de la mama, insatisfacción de la imagen corporal, el estado emocional, el funcionamiento social y sexual. Todas estas mujeres presentan una o más secuelas aunque sean en un grado leve. Más del 80% de estas mujeres, padecen problemas del brazo, alteraciones del estado físico, mal estado emocional. Palabras clave: cáncer de mama, calidad de vida, supervivientes, enfermería. “A STUDY OF THE QUALITY OF LIFE OF WOMEN WHO HAVE SURVIVED BREAST CANCER” Introduction Breast cancer is a health problem with great repercussions given its high rate of prevalence in the female population. Given that its prognosis has improved notably in recent years and survival is currently high, the process itself and the treatments that can be applied have important repercussions for patients and their relatives. Currently, breast cancer is not perceived as being a terminal illness, but rather as a long term chronic process with statistics confirming that this is a serious threat for women given the after-effects it causes. Aims 1) To study the Quality of Life (QOL) of women who have survived a 5 to 8 year period of breast cancer, identifying the physical and psychological after-effects that they suffer from. 2) To determine the percentage of women who have survived a 5 to 8 year period of breast cancer and suffer from all of the kinds of after-effects. 3) To determine the percentage of women who have survived between 5 and 8 years of breast cancer and who have an altered QOL. 4) To analyze which sociodemographic and clinical factors are related to the severity of the after-effects and therefore have an influence on the QOL of these women. Methodology The study was observational and transversal including 120 women who had survived between 5 and 8 years of diagnosed breast cancer. Instrument of measurement: adapted EORTC QLQ-C30+ BR23 questionnaires. Data analysis was carried out using different statistical tests (a descriptive analysis, absolute and relative frequency distribution, factor analysis, parameter estimates with a confidence intervals of 95%, the contrast of proportion, the Pearson Correlation Coefficient calculator, Pearson's χ2 test , T-Student's combined test and the Brown-Forsythe non-exact test). Results The mean age of the subjects in the sample was 51.76 years (SD 8.97), 72.5% were married, 46.7% had 2 children, 38.3% had been subjected to conservative surgery, and 58.3% received chemotherapy+radiotherapy+hormone therapy. After carrying out the factor analysis the following most notable dimensions were affected: problems with one's arm (22.5% of these women had an altered QOL), physical state (20%), satisfaction with one's body image (22.5%), emotional state (20.8%), social functioning (7.5%), sexual functioning (60%), eating disorders (2.5%) and discomfort in the breast (38.3%). Conclusion Three out of four women who had survived between 5 and 8 years of breast cancer had an altered QOL that was affected by the following after-effects: problems with one's arm, eating disorders, breast problems, dissatisfaction with one's body image, one's emotional state, and social and sexual functioning. All the women had at least one of these after-effects even if they were only slight. More than 80% of these women suffered from problems with their arms, had an alteration in their physical state, or were in a poor emotional state. Key words: breast cancer, quality of life, survivors, nursing.
Open Access
La musicoterapia como asignatura en los estudios de grado en enfermería
(Murcia: Servicio de publicaciones de la Universidad de Murcia., 2019) López Núñez, Norberto; Seva Llor, Ana Myriam; Ramis Vidal, Manuel Guillermo; Martínez Alarcón, Laura; Ruiz Carreño, Paula
Introducción:La musicoterapia se entiende por el uso de la música o sus elementos con fines terapéuticos. Su empleo en la enfermería es escaso más allá del uso de la intervención NIC 4400. Objetivo:Conocer y analizar el grado de aceptación por parte de los estudiantes de enfermería ante la posible inclusión de la musicoterapia como asignatura en los programas educativos de los estudios de Grado en Enfermería. Método:Se ha realizado un estudio observacional descriptivo de corte transversal con una muestra n=346 participantes.Resultados: Los resultados muestran que el 93,93% de los alumnos sí incluirían la musicoterapia como una asignatura Optativa en los estudios de Grado en Enfermería, haciendo uso de ella en su futuro profesional.